Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 601–700 of 1,000
MacLehose, R. F., Zakai, N. A., Walker, R. F., Alonso, Á., Adams, T., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12514 · Cited by 5
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients
Villanueva‐Bueno, C., Escudero‐Vilaplana, V., Collado‐Borrell, R., Giménez‐Manzorro, Á., Ribed, A., Marzal-Alfaro, B., Revuelta-Herrero, J. L., González-Haba, E., Herranz, A., & Sanjurjo‐Sáez, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1965990 · Cited by 5
Shaydakov, M. E., Ting, W., Sadek, M., Aziz, F., Diaz, J. A., Comerota, A. J., Lurie, F., Blebea, J., Eklöf, B., Lugli, M., et al. (2022) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2022.03.013 · Cited by 6
The use of novel oral anticoagulants in cancer patients with venous thromboembolism
Karakatsanis, S., Roumpi, A., & Syrigos, K. N. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.009 · Cited by 5
Weiler, B. A., Marciniak, E. T., Reed, R. M., & McCurdy, M. T. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-203910 · Cited by 5
Spotlight on real-world evidence for the treatment of DVT: XALIA
Turpie, A. G. G., & Ageno, W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0488 · Cited by 5
“NOACs have been evaluated for the secondary prevention of recurrent VTE and appear to be effective agents in this setting, with an acceptable risk of bleeding (12, 48, 49), although further data are warranted to provide comprehensive evidence on optimal treatment duration in everyday clinical practice.”
BackgroundLaunay‐Vacher, V., Scotté, F., Riess, H. B., Ashman, N., McFarlane, P. A., Ribic, C. M., & Elalamy, I. (2018) · Journal of Onco-Nephrology · doi:10.1177/2399369318809102 · Cited by 6
Extended anticoagulation in venous thromboembolism.
Schulman, S. (2013) · PubMed · doi:10.1056/nejmc1304815 · Cited by 4
The Newer Anticoagulants in Thrombosis Control in Cancer Patients
den Exter, P. L., van der Hulle, T., Klok, F. A., & Huisman, M. V. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.014 · Cited by 4
“In the RE-MEDY study, a randomized, double blind superiority trial, extended treatment with dabigatran (150 mg twice daily) was compared to warfarin for the long-term management of VTE and enrolled patients with acute VTE that had successfully been treated with anticoagulants for a period of 3 to 6 months [41].”
MethodAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_16 · Cited by 6
Major acute cardiovascular events after venous thromboembolism: a meta-analysis of randomized trials
Becattini, C., & Vedovati, M. C. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.02.023 · Cited by 4
Kang, H., Dietrich, E. A., Huang, P., Lo‐Ciganic, W., DeRemer, C. E., & Park, H. (2023) · Clinical and Translational Science · doi:10.1111/cts.13510 · Cited by 5
Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa
Vu, K., Kar, S., Goyal, N., Mottamal, M., Afosah, D. K., & Al‐Horani, R. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c04518 · Cited by 4
Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors
Dumas, A., Goyal, N., Mottamal, M., Afosah, D. K., & Al‐Horani, R. A. (2024) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-024-03054-2 · Cited by 4
Bilal, A. R., Umar, S. A., Arfin, S. M. W., Bilal, A. R., Sajid, M., Gaba, H., Qureshi, S., Inam, M. H., & Waqas, S. A. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03172-5 · Cited by 4
“In the United States alone, VTE is responsible offering significantly lower rates of major bleeding [ 6 –8 ].”
Lingohr, A. A. M. (2015) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000209 · Cited by 4
“The clinical event rates were estimated from the published data of the clinical trials, RE-SONATE, EINSTEN-EXT, and AMPLIFY-EXT as done for prior analyses [24,46,47].”
MethodUse of aspirin for the prevention of lower extremity deep venous thrombosis
Sadaghianloo, N., Jean‐Baptiste, E., Declémy, S., Hassen‐Khodja, R., & Dardik, A. (2014) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2013.10.051 · Cited by 4
New oral anticoagulants: An emergency department overview
Wood, P. (2013) · Emergency Medicine Australasia · doi:10.1111/1742-6723.12156 · Cited by 4
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism
Imberti, D., & Benedetti, R. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613503397 · Cited by 4
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Tratamiento de la trombosis venosa profunda de extremidades inferiores
Trujillo‐Santos, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.05.009 · Cited by 10
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Eyster, M. E., & Woller, S. C. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12740 · Cited by 4
Camporese, G., Bernardi, E., Bortoluzzi, C., Noventa, F., Simioni, P., & for the METRO Investigator Study Group (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02896-6 · Cited by 4
Elshafei, M. N., El‐Bardissy, A., SALEM, M. R., Abdelmoneim, M. S., Khalil, A., Elhadad, S., & Danjuma, M. I.-M. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00628-6 · Cited by 4
“Although previous reviews, as well as some international guidelines, have suggested the avoidance of DOACs in patients with LBW [23, 40], our recommendation, especially with regard to stroke patients, is prescriptive and explicit; they should be considered reliable and safe in this cohort of…”
BackgroundMethodAnticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations
Parks, A. L., Stevens, S. M., & Woller, S. C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109097 · Cited by 4
del Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2024.07.007 · Cited by 4
Mearns, E. S., Hawthorne, J., Song, J.-S., & Coleman, C. I. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005379 · Cited by 5
Phan, K. H., Lloyd, D., Wilson-Smith, A., Leung, V., & Andric, M. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312198 · Cited by 5
Kanaan, D. M., Cook, B. M., Kelly, J., & Malloy, R. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.009 · Cited by 4
Zakai, N. A., Walker, R. F., MacLehose, R. F., Koh, I., Alonso, Á., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12575 · Cited by 4
Hydrodynamic Cavitation‐Induced Thrombolysis on a Clot‐on‐a‐Chip Platform
Özogul, B., Akar, Ü., Mercimek, R., Talabazar, F. R., Sarraf, S. S., Aghdam, A. S., Hamedani, A. A., Villanueva, L. G., Grishenkov, D., Amani, E., et al. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202400112 · Cited by 4
Novel Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Oliphant, C. S., Jacobs, A. R., Kabra, R., & Das, P. (2013) · Future Cardiology · doi:10.2217/fca.13.76 · Cited by 4
“001) [21]”
BackgroundA pharmacotherapy review of the novel, oral antithrombotics
Walters, K. J., Meador, A. E., Galdo, J. A., & Ciarrocca, K. N. (2016) · Special Care in Dentistry · doi:10.1111/scd.12207 · Cited by 4
Neue orale direkte Antikoagulanzien: Viele Vorteile, aber offene Fragen
Haas, S. K., & Schellong, S. (2014) · Der Internist · doi:10.1007/s00108-013-3424-3 · Cited by 5
Self-citationdel Molino, F., González, I. M., & Saperas, E. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.02.014 · Cited by 4
Perioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants
Barnes, G. D., Eagle, K. A., & Froehlich, J. B. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1118 · Cited by 4
Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review.
Ganji, R., Ala, S., Aarabi, M., Baghery, B., & Salehifar, E. (2016) · PubMed Central · Cited by 7
Diagnosis, prognosis and therapeutic management of acute pulmonary embolism
Tapson, V. F. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1210471 · Cited by 5
“Dabigatran decreased major bleeding and major or CRNM bleeding compared with warfarin [44].”
BackgroundInfluentialPrevention and Treatment of Venous Thromboembolism
Streiff, M. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00016-9 · Cited by 6
Zeng, J., Zhang, X., Lip, G. Y. H., Shu, X., Thabane, L., Tian, J., & Li, G. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619853629 · Cited by 4
Toorop, M. M. A., Scheres, L. J. J., & Lijfering, W. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15248 · Cited by 4
Top practice-changing articles over the last two years
Kaatz, S., & Gage, B. F. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0896-x · Cited by 3
The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease
Bott‐Kitslaar, D. M., Wysokiński, W. E., & McBane, R. D. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0326-1 · Cited by 3
Pharmacological management of pulmonary embolism
Gouin, B., Robert‐Ebadi, H., Righini, M., & Blondon, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1268122 · Cited by 3
Diagnose und Behandlung der Lungenembolie: Einsatz neuer oraler Antikoagulanzien (NOAK)
Hecker, M., Mayer, K., & Bauer, P. (2017) · CME · doi:10.1007/s11298-017-5986-1 · Cited by 3
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Radke, P. W., & Möckel, M. (2017) · Herz · doi:10.1007/s00059-017-4655-1 · Cited by 3
“In der RE-MEDY-Studie zeigte sich an 2866 Patienten, bei denen Dabigatran (2-mal 150mg/Tag) gegen Warfarin (INR: 2,0–3,0) randomisiert wurde, eine Nichtunterlegenheit von Dabigatran hinsichtlich erneuter thromboembolischer (einschließlich tödlicher) Rezidive bei nicht signifikant unterschiedlichem Risiko schwerwiegend…”
BackgroundAntidotbehandling ved bruk av direktevirkende antikoagulasjonsmidler
Rutherford, O.-C. W., König, M. S. S., Risnes, K., Raouf, N., Atar, D., & Ghanima, W. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0190 · Cited by 3
Chazova, I. E., Martynyuk, T. V., Горбачевский, С. В., Владимирович, Г. В., Danilov, N. M., Панченко, Е. П., Chernyavskiy, A. М., Shmalts, A. A., & Yavelov, I. S. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.09.201836 · Cited by 3
Gołąb, A., Plicner, D., Konieczyńska, M., Broniatowska, E., & Undas, A. (2024) · Medicine · doi:10.1097/md.0000000000038697 · Cited by 3
“32] A multicenter cohort study by Bortoluzzi et al, who evaluated 450 unprovoked VTE patients on rivaroxaban (more than 60% patients received longer than 2 years of treatment, and around 20% completed the 5-year therapy), showed that the incidence rate of VTE recurrence was 1.7 per 100 person–years…”
BackgroundInfluentialControversies and challenges of anticoagulation therapy in obesity
SALMON, T. W., & Lip, G. Y. H. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2462766 · Cited by 4
D’Abrantes, S., Male, C., Brown, N., Bjursell, M., Ambery, P., Berggren, A., & Mattsson, U. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323137 · Cited by 4
“[28–30].”
Oral Anticoagulants in Women: What's the Difference? A Narrative Review
Faioni, E. M., & Scimeca, B. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251347938 · Cited by 3
A case of post varicella cortical venous thrombosis successfully treated with dabigatran
Mathew, T., Lobo, A., Sarma, G. R. K., & Nadig, R. (2013) · Neurology India · doi:10.4103/0028-3886.121939 · Cited by 3
Nouveaux anticoagulants oraux dans le traitement curatif de la maladie thromboembolique veineuse
Bertoletti, L., Lega, J., Moulin, N., Buchmuller, A., Mismetti, P., & Decousus, H. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.06.001 · Cited by 4
Self-citationLiem, T. K., & DeLoughery, T. G. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101317 · Cited by 3
Anticoagulation after venous thromboembolism: Deciding on the optimal duration
Eichinger, S. (2013) · Hämostaseologie · doi:10.5482/hamo-13-03-0015 · Cited by 3
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_2 · Cited by 3
Piovella, F., & Iosub, D. I. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.001 · Cited by 3
Xie, R., Li, L., Chen, L., Wan, L., Chen, B., Jiang, J., Huang, H., Li, Y., He, Y., Lv, J., et al. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2829 · Cited by 3
Giustozzi, M., Vedovati, M. C., & Agnelli, G. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000697 · Cited by 3
Akute Beinvenenthrombose – moderne Diagnostik und Therapie
Thrombose-Initiative e., V., Kröger, K., & Moerchel, C. (2019) · Der Chirurg · doi:10.1007/s00104-018-0771-6 · Cited by 3
Rainville, T., Laskine, M., & Durand, M. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111057 · Cited by 3
Therapeutic Advances in Emergency Cardiology: Acute Pulmonary Embolism
Petriş, A. O., Konstantinides, S., Ţînţ, D., Cimpoesu, D. C., & Pop, C. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000917 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
“In four major randomized clinical trials, dabigatran [26], rivaroxaban [27,28], and apixaban [29] have all been investigated for extended treatment (after initial acute treatment in 3–18 months).”
BackgroundDecision-Making in the Management of Venous Thromboembolism
Ellis, M. H., & Avnery, O. H. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.027 · Cited by 3
Place actuelle des anticoagulants oraux directs dans la maladie thromboembolique veineuse
Roffé, A., Guédon, A. F., & Lallmahomed, E. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.06.005 · Cited by 4
VTE and anticoagulation in menstruating women
Micaily, I., & Bannow, B. S. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100088 · Cited by 3
Antithrombotika und Antihämorrhagika
Wille, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_17 · Cited by 3
Ren, J., Wang, N., Zhang, X., Song, F., Zheng, X. M., & Han, X. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05767-z · Cited by 3
“Advanced age is a significant risk factor for thrombotic diseases and is asso - ciated with increased morbidity [2, 3].”
Laganà, A., Fucci, L., Sorella, S., Santoro, C., & Chistolini, A. (2024) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001321 · Cited by 3
Warwar, A., Zargari, I., Stein, N., Zoubi, I., Muhammad, E., Perek, S., Naamneh, M., Preis, M., & Saliba, W. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.108258 · Cited by 3
Law, E. H., & Leung, T. S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s70299 · Cited by 3
“Extended treatment of VTE with DOACs has been studied for treatment durations between 12 and 36 months.(21,22,25) While all of the DOACs demonstrated a statistically significant reduction in recurrent VTE after patients had been on acute treatment for at least 6 months, only dabigatran has been studied against an acti…”
Treatment of Venous Thromboembolism
Rose, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-22602-6_7 · Cited by 3
Cho, J. H. (2015) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.15002 · Cited by 3
Innasimuthu, A. L., Kumar, S., Akter, S., & BORER, J. S. (2013) · Cardiology · doi:10.1159/000353484 · Cited by 3
Dabigatran etexilate for venous thromboembolism: a safety evaluation
Brown, R., Lip, G. Y. H., & Gallego, P. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.895321 · Cited by 4
Dabigatran for the treatment of venous thromboembolism
Schellong, S. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1052400 · Cited by 3
“Both studies included a follow-up visit 30 days after the end of treatment, but for RE-SONATE the follow-up period was extended to 12 months [43].”
BackgroundMethodResultInfluentialSelf-citationAnticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature
Nunnally, B., Josseaume, J., Duchateau, F. X., O’Connor, R. E., Verner, L., & Brady, W. J. (2015) · Air Medical Journal · doi:10.1016/j.amj.2015.06.006 · Cited by 3
Stoberock, K., Debus, E. S., Larena-Avellaneda, A. A., & Kieback, A. G. (2013) · Gefässchirurgie · doi:10.1007/s00772-013-1186-9 · Cited by 3
Modern Approaches to Implantation of Cava-Filters at Life-Threatening Pulmonary Embolism
SHARAFEEV, A. Z., & Gluschenko, L. V. (2016) · Novosti hirurgii · doi:10.18484/2305-0047.2016.2.177 · Cited by 3
New anticoagulants in cancer patient treatments
Arobelidze, S., Haddad, A. S., Spiro, T. P., & Daw, H. A. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000404 · Cited by 3
Gong, X., Wang, H., & Yuan, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3610 · Cited by 3
“The annual risk of bleeding for vitamin K antagonists is 1‑3%, and this value is not substantially reduced by treatment with newer oral anticoagulant therapy (5,6).”
Krumme, A. A., Pawar, A. M., Schneeweiß, S., Glynn, R. J., Choudhry, N. K., Kulldorff, M., Ortiz, A. S., Avorn, J., & Gagne, J. J. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0053 · Cited by 3
Pharmacologic Reversal of Direct Oral Anticoagulants
Farina, N., & Miller, J. T. (2018) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000193 · Cited by 3
Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?
Carman, T. L. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.002 · Cited by 3
Treatment of deep vein thrombosis
Lauw, M. N., & Buller, H. R. (2014) · doi:10.2217/fmeb2013.13.98 · Cited by 5
The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy
Elmi, G., Pizzini, A. M., & Silingardi, M. (2018) · Vascular · doi:10.1177/1708538118776896 · Cited by 3
Outpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 4
Kilinc, M., Yaylalı, Y. T., Yıldızeli, B., & Taş, S. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2020.01.016 · Cited by 3
“In RE-MEDY (Re-medy is Secondary Prevention of Venous Thrombo Embolism [VTE]; NCT00329238), 48% of patients were tested for thrombophilia, and 38% of these patients tested positive (11).”
BackgroundPulmonary artery thrombosis: strategy of anticoagulation
Porembskaya, О. Y., Кравчук, В. Н., Lobastov, K. V., Kuzmina-Krutetskaya, S. R., Laberko, L. A., Chesnokov, M. S., Velikanova, K. E., & Saiganov, S. A. (2021) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia202111176 · Cited by 4
Sandoval, J. D. G., Cerón, D. K. R., Bastidas-Sánchez, B. E., & Arcila, H. F. L. (2021) · Repositorio Institucional Universidad El Bosque · doi:10.18270/rsb.v11i1.3351 · Cited by 3
Is there a role yet for new direct oral anticoagulants in cancer patients?
Cohen, A. L., Lim, C. S., & Davies, A. H. (2015) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355515604255 · Cited by 3
Achilles, A., Mohring, A., Zeus, T., Kelm, M., & Polzin, A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13718 · Cited by 4
Gagnon, É., Girard, A. S., Bourgault, J., Abner, E., Gill, D., Thériault, S., Vohl, M., Tchernof, A., Esko, T., Mathieu, P., et al. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae043 · Cited by 2
“29,30 Direct thrombin inhibitors specifically inhibit the intrinsic activity of the F2 gene product: the protein thrombin.”
InfluentialZhang, S., Li, Y., Yang, Y., Gong, S., Yang, Z., Hong, C., Cui, X., Wan, J., Ji, Y., Chen, H., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03042-5 · Cited by 2
Xie, Y., Huang, Y., Stevenson, H. C. S., Li, Y., Zhang, K., Islam, Z. H., Marcum, W. A., Johnston, C., Hoyt, N. E., Kent, E. W., et al. (2024) · Annals of Biomedical Engineering · doi:10.1007/s10439-024-03609-7 · Cited by 3
Practical guide to management after an acute pulmonary embolism
Alikhan, R., Howard, L., Johnson, M., Sweeney, S., Kiely, D. G., & Pepke‐Żaba, J. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003028 · Cited by 2
Brodmann, M. (2013) · Hämostaseologie · doi:10.5482/hamo-13-02-0005 · Cited by 3
Jiménez, D., & Uresandi, F. (2014) · Angiología · doi:10.1016/j.angio.2014.02.003 · Cited by 3
Endovascular Treatment of Deep Vein Thrombosis
Javier, J. J. (2014) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2014.07.003 · Cited by 2
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.